Sales of Gilead’s COVID-19 drug top $800 million

Gilead Sciences Inc. late Thursday swung to profit and reported rising sales thanks to its COVID-19 drug, but a revenue drop from two of its HIV drugs and ongoing concerns about the pandemic dragged the stock lower.